Cyclodextrin has conflicting actions on autophagy flux in vivo in brains of normal and Alzheimer model mice

Dun Sheng Yang, Philip Stavrides, Asok Kumar, Ying Jiang, Panaiyur S. Mohan, Masuo Ohno, Kostantin Dobrenis, Cristin D. Davidson, Mitsuo Saito, Monika Pawlik, Chunfeng Huo, Steven U. Walkley, Ralph A. Nixon

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

2-hydroxypropyl-b-cyclodextrin (CYCLO), a modifier of cholesterol efflux from cellular membrane and endo-lysosomal compartments, reduces lysosomal lipid accumulations and has therapeutic effects in animal models of Niemann-Pick disease type C and several other neurodegenerative states. Here, we investigated CYCLO effects on autophagy in wild-type mice and TgCRND8 mice-an Alzheimer's Disease (AD) model exhibiting b-amyloidosis, neuronal autophagy deficits leading to protein and lipid accumulation within greatly enlarged autolysosomes. A 14-day intracerebroventricular administration of CYCLO to 8-month-old TgCRND8 mice that exhibit moderately advanced neuropathology markedly diminished the sizes of enlarged autolysosomes and lowered their content of GM2 ganglioside and Ab-immunoreactivity without detectably altering amyloid precursor protein processing or extracellular Ab/b-amyloid burden. We identified two major actions of CYCLO on autophagy underlying amelioration of lysosomal pathology. First, CYCLO stimulated lysosomal proteolytic activity by increasing cathepsin D activity, levels of cathepsins B and D and two proteins known to interact with cathepsin D, NPC1 and ABCA1. Second, CYCLO impeded autophagosome-lysosome fusion as evidenced by the accumulation of LC3, SQSTM1/p62, and ubiquitinated substrates in an expanded population of autophagosomes in the absence of greater autophagy induction. By slowing substrate delivery to lysosomes, autophagosome maturational delay, as further confirmed by our in vitro studies, may relieve lysosomal stress due to accumulated substrates. These findings provide in vivo evidence for lysosomal enhancing properties of CYCLO, but caution that prolonged interference with cellular membrane fusion/autophagosome maturation could have unfavorable consequences, which might require careful optimization of dosage and dosing schedules.

Original languageEnglish (US)
Article numberddx001
Pages (from-to)843-859
Number of pages17
JournalHuman Molecular Genetics
Volume26
Issue number5
DOIs
StatePublished - Mar 1 2017

Fingerprint

Autophagy
Cyclodextrins
Cathepsin D
Brain
Lysosomes
G(M2) Ganglioside
Type C Niemann-Pick Disease
Lipids
Cathepsin B
Membrane Fusion
Amyloid beta-Protein Precursor
Therapeutic Uses
Amyloidosis
Amyloid
Appointments and Schedules
Alzheimer Disease
Proteins
Animal Models
Cholesterol
Pathology

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Genetics(clinical)

Cite this

Yang, D. S., Stavrides, P., Kumar, A., Jiang, Y., Mohan, P. S., Ohno, M., ... Nixon, R. A. (2017). Cyclodextrin has conflicting actions on autophagy flux in vivo in brains of normal and Alzheimer model mice. Human Molecular Genetics, 26(5), 843-859. [ddx001]. https://doi.org/10.1093/hmg/ddx001

Cyclodextrin has conflicting actions on autophagy flux in vivo in brains of normal and Alzheimer model mice. / Yang, Dun Sheng; Stavrides, Philip; Kumar, Asok; Jiang, Ying; Mohan, Panaiyur S.; Ohno, Masuo; Dobrenis, Kostantin; Davidson, Cristin D.; Saito, Mitsuo; Pawlik, Monika; Huo, Chunfeng; Walkley, Steven U.; Nixon, Ralph A.

In: Human Molecular Genetics, Vol. 26, No. 5, ddx001, 01.03.2017, p. 843-859.

Research output: Contribution to journalArticle

Yang, DS, Stavrides, P, Kumar, A, Jiang, Y, Mohan, PS, Ohno, M, Dobrenis, K, Davidson, CD, Saito, M, Pawlik, M, Huo, C, Walkley, SU & Nixon, RA 2017, 'Cyclodextrin has conflicting actions on autophagy flux in vivo in brains of normal and Alzheimer model mice', Human Molecular Genetics, vol. 26, no. 5, ddx001, pp. 843-859. https://doi.org/10.1093/hmg/ddx001
Yang, Dun Sheng ; Stavrides, Philip ; Kumar, Asok ; Jiang, Ying ; Mohan, Panaiyur S. ; Ohno, Masuo ; Dobrenis, Kostantin ; Davidson, Cristin D. ; Saito, Mitsuo ; Pawlik, Monika ; Huo, Chunfeng ; Walkley, Steven U. ; Nixon, Ralph A. / Cyclodextrin has conflicting actions on autophagy flux in vivo in brains of normal and Alzheimer model mice. In: Human Molecular Genetics. 2017 ; Vol. 26, No. 5. pp. 843-859.
@article{3ead3be8d2744f779d2851eb2da7b6e0,
title = "Cyclodextrin has conflicting actions on autophagy flux in vivo in brains of normal and Alzheimer model mice",
abstract = "2-hydroxypropyl-b-cyclodextrin (CYCLO), a modifier of cholesterol efflux from cellular membrane and endo-lysosomal compartments, reduces lysosomal lipid accumulations and has therapeutic effects in animal models of Niemann-Pick disease type C and several other neurodegenerative states. Here, we investigated CYCLO effects on autophagy in wild-type mice and TgCRND8 mice-an Alzheimer's Disease (AD) model exhibiting b-amyloidosis, neuronal autophagy deficits leading to protein and lipid accumulation within greatly enlarged autolysosomes. A 14-day intracerebroventricular administration of CYCLO to 8-month-old TgCRND8 mice that exhibit moderately advanced neuropathology markedly diminished the sizes of enlarged autolysosomes and lowered their content of GM2 ganglioside and Ab-immunoreactivity without detectably altering amyloid precursor protein processing or extracellular Ab/b-amyloid burden. We identified two major actions of CYCLO on autophagy underlying amelioration of lysosomal pathology. First, CYCLO stimulated lysosomal proteolytic activity by increasing cathepsin D activity, levels of cathepsins B and D and two proteins known to interact with cathepsin D, NPC1 and ABCA1. Second, CYCLO impeded autophagosome-lysosome fusion as evidenced by the accumulation of LC3, SQSTM1/p62, and ubiquitinated substrates in an expanded population of autophagosomes in the absence of greater autophagy induction. By slowing substrate delivery to lysosomes, autophagosome maturational delay, as further confirmed by our in vitro studies, may relieve lysosomal stress due to accumulated substrates. These findings provide in vivo evidence for lysosomal enhancing properties of CYCLO, but caution that prolonged interference with cellular membrane fusion/autophagosome maturation could have unfavorable consequences, which might require careful optimization of dosage and dosing schedules.",
author = "Yang, {Dun Sheng} and Philip Stavrides and Asok Kumar and Ying Jiang and Mohan, {Panaiyur S.} and Masuo Ohno and Kostantin Dobrenis and Davidson, {Cristin D.} and Mitsuo Saito and Monika Pawlik and Chunfeng Huo and Walkley, {Steven U.} and Nixon, {Ralph A.}",
year = "2017",
month = "3",
day = "1",
doi = "10.1093/hmg/ddx001",
language = "English (US)",
volume = "26",
pages = "843--859",
journal = "Human Molecular Genetics",
issn = "0964-6906",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - Cyclodextrin has conflicting actions on autophagy flux in vivo in brains of normal and Alzheimer model mice

AU - Yang, Dun Sheng

AU - Stavrides, Philip

AU - Kumar, Asok

AU - Jiang, Ying

AU - Mohan, Panaiyur S.

AU - Ohno, Masuo

AU - Dobrenis, Kostantin

AU - Davidson, Cristin D.

AU - Saito, Mitsuo

AU - Pawlik, Monika

AU - Huo, Chunfeng

AU - Walkley, Steven U.

AU - Nixon, Ralph A.

PY - 2017/3/1

Y1 - 2017/3/1

N2 - 2-hydroxypropyl-b-cyclodextrin (CYCLO), a modifier of cholesterol efflux from cellular membrane and endo-lysosomal compartments, reduces lysosomal lipid accumulations and has therapeutic effects in animal models of Niemann-Pick disease type C and several other neurodegenerative states. Here, we investigated CYCLO effects on autophagy in wild-type mice and TgCRND8 mice-an Alzheimer's Disease (AD) model exhibiting b-amyloidosis, neuronal autophagy deficits leading to protein and lipid accumulation within greatly enlarged autolysosomes. A 14-day intracerebroventricular administration of CYCLO to 8-month-old TgCRND8 mice that exhibit moderately advanced neuropathology markedly diminished the sizes of enlarged autolysosomes and lowered their content of GM2 ganglioside and Ab-immunoreactivity without detectably altering amyloid precursor protein processing or extracellular Ab/b-amyloid burden. We identified two major actions of CYCLO on autophagy underlying amelioration of lysosomal pathology. First, CYCLO stimulated lysosomal proteolytic activity by increasing cathepsin D activity, levels of cathepsins B and D and two proteins known to interact with cathepsin D, NPC1 and ABCA1. Second, CYCLO impeded autophagosome-lysosome fusion as evidenced by the accumulation of LC3, SQSTM1/p62, and ubiquitinated substrates in an expanded population of autophagosomes in the absence of greater autophagy induction. By slowing substrate delivery to lysosomes, autophagosome maturational delay, as further confirmed by our in vitro studies, may relieve lysosomal stress due to accumulated substrates. These findings provide in vivo evidence for lysosomal enhancing properties of CYCLO, but caution that prolonged interference with cellular membrane fusion/autophagosome maturation could have unfavorable consequences, which might require careful optimization of dosage and dosing schedules.

AB - 2-hydroxypropyl-b-cyclodextrin (CYCLO), a modifier of cholesterol efflux from cellular membrane and endo-lysosomal compartments, reduces lysosomal lipid accumulations and has therapeutic effects in animal models of Niemann-Pick disease type C and several other neurodegenerative states. Here, we investigated CYCLO effects on autophagy in wild-type mice and TgCRND8 mice-an Alzheimer's Disease (AD) model exhibiting b-amyloidosis, neuronal autophagy deficits leading to protein and lipid accumulation within greatly enlarged autolysosomes. A 14-day intracerebroventricular administration of CYCLO to 8-month-old TgCRND8 mice that exhibit moderately advanced neuropathology markedly diminished the sizes of enlarged autolysosomes and lowered their content of GM2 ganglioside and Ab-immunoreactivity without detectably altering amyloid precursor protein processing or extracellular Ab/b-amyloid burden. We identified two major actions of CYCLO on autophagy underlying amelioration of lysosomal pathology. First, CYCLO stimulated lysosomal proteolytic activity by increasing cathepsin D activity, levels of cathepsins B and D and two proteins known to interact with cathepsin D, NPC1 and ABCA1. Second, CYCLO impeded autophagosome-lysosome fusion as evidenced by the accumulation of LC3, SQSTM1/p62, and ubiquitinated substrates in an expanded population of autophagosomes in the absence of greater autophagy induction. By slowing substrate delivery to lysosomes, autophagosome maturational delay, as further confirmed by our in vitro studies, may relieve lysosomal stress due to accumulated substrates. These findings provide in vivo evidence for lysosomal enhancing properties of CYCLO, but caution that prolonged interference with cellular membrane fusion/autophagosome maturation could have unfavorable consequences, which might require careful optimization of dosage and dosing schedules.

UR - http://www.scopus.com/inward/record.url?scp=85019053494&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019053494&partnerID=8YFLogxK

U2 - 10.1093/hmg/ddx001

DO - 10.1093/hmg/ddx001

M3 - Article

C2 - 28062666

AN - SCOPUS:85019053494

VL - 26

SP - 843

EP - 859

JO - Human Molecular Genetics

JF - Human Molecular Genetics

SN - 0964-6906

IS - 5

M1 - ddx001

ER -